Sarepta Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Sarepta Therapeutics reported a significant net loss of $713.4 million in 2025, driven by increased R&D expenses for new collaborations and substantial inventory write-offs, alongside critical safety updates for ELEVIDYS and a primary endpoint miss in the ESSENCE trial.
NASDAQ
10-K: Sarepta Therapeutics Reports Strong 2024 Results, Expands Pipeline with Arrowhead Collaboration
Sarepta Therapeutics' 2024 10-K filing highlights significant revenue growth driven by ELEVIDYS, strategic collaborations, and ongoing development of genetic therapies for rare diseases.
NASDAQ
Sarepta Therapeutics and Roche have further amended their licensing agreement for Sarepta's Duchenne muscular dystrophy gene therapy, SRP-9001, adjusting supply agreement deadlines.